Patterns of injecting and non-injecting drug use by sexual behaviour in people who inject drugs attending services in England, Wales and Northern Ireland, 2013-2016. by Heinsbroek, E et al.
 Heinsbroek, E, Glass, R, Edmundson, C, Hope, V and Desai, M
 Patterns of injecting and non-injecting drug use by sexual behaviour in people 
who inject drugs attending services in England, Wales and Northern Ireland, 
2013-2016.
http://researchonline.ljmu.ac.uk/8358/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Heinsbroek, E, Glass, R, Edmundson, C, Hope, V and Desai, M (2018) 
Patterns of injecting and non-injecting drug use by sexual behaviour in 
people who inject drugs attending services in England, Wales and Northern 
Ireland, 2013-2016. International Journal of Drug Policy. ISSN 0955-3959 
LJMU Research Online
1 
 
Patterns of injecting and non-injecting drug use by sexual behaviour in 1 
people who inject drugs attending services in England, Wales and Northern 2 
Ireland, 2013-2016 3 
 4 
Ellen Heinsbroeka, Rachel Glassa, Claire  Edmundsona, Vivian Hopea,b, Monica Desaia 5 
a. HIV & STI Department, National Infection Service, Public Health England, 61 Colindale Avenue, 6 
London, NW9 5EQ, United Kingdom 7 
b. Public Health Institute, Liverpool John Moores University, 2nd Floor Henry Cotton Campus, 15-21 8 
Webster Street, Liverpool L3 2ET, United Kingdom 9 
ellen.heinsbroek@phe.gov.uk; rachel.glass@phe.gov.uk; claire.edmundson@phe.gov.uk; 10 
vivian.hope@phe.gov.uk; monica.desai@phe.gov.uk 11 
 12 
Corresponding author: 13 
Dr Ellen Heinsbroek  14 
Drug Use & Infections Team, HIV & STI Department 15 
National Infection Service, Public Health England 16 
61 Colindale Avenue, London, NW9 5EQ, United Kingdom 17 
Ellen.Heinsbroek@phe.gov.uk 18 
Tel: 020 8327 7311  19 
  20 
2 
 
Patterns of injecting and non-injecting drug use by sexual behaviour in people who inject drugs 21 
attending services in England, Wales and Northern Ireland, 2013-2016 22 
Keywords: LGBT, homosexuals, sexualised drug use, chemsex, people who inject drugs 23 
Abstract 24 
Background 25 
Higher levels of drug use have been reported in lesbian, gay, bisexual and transgender (LGBT) 26 
communities, some of which can be explained by sexualised drug use, including ͚cheŵseǆ͛; the use 27 
of drugs before or during planned sexual activity to sustain, enhance, disinhibit or facilitate sex. We 28 
explored injecting and non-injecting drug use by sexual behaviour among people who inject drugs 29 
(PWID) in England, Wales and Northern Ireland. 30 
Methods 31 
Data were used from an unlinked-anonymous survey of PWID (2013-2016), where participants 32 
recruited through services self-completed a questionnaire. We included sexually active participants 33 
who had injected in the previous year, and compared injecting and non-injecting drug use between 34 
men reporting sex with men (MSM) and heterosexual men, and between women reporting sex with 35 
women (WSW) and heterosexual women. The questionnaire did not include GHB/GBL and 36 
methamphetamine use. 37 
Results 38 
There were 299 MSM, 3,215 heterosexual male, 122 WSW and 1,336 heterosexual female 39 
participants. MSM were more likely than heterosexual men to use drugs associated with chemsex: 40 
injected or non-injected mephedrone (adjusted OR (AOR) 2.22, 95%CI 1.54-3.22; AOR 2.15, 95%CI 41 
1.48-3.11) and injected or non-injected ketamine (AOR 1.98, 95%CI 1.29-3.05; AOR 2.57, 95%CI 1.59-42 
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4.15). MSM were also more likely to inject methadone, inhale solvents, take ecstasy, cocaine or 43 
speed.  44 
WSW were more likely than heterosexual women to use non-injected mephedrone (AOR 2.19, 45 
95%CI 1.20-3.99) and use injected or non-injected ketamine (AOR 5.58, 95%CI 2.74-11.4; AOR 3.05, 46 
95%CI 1.30-7.19). WSW were also more likely to inject methadone, inject cocaine, use non-injected 47 
cocaine, crack, benzodiazepines or ecstasy, inhale solvents, or smoke cannabis.  48 
Conclusion 49 
Injecting and non-injecting drug use differed between MSM/WSW and heterosexual men and 50 
women. The use of drugs that have been associated with chemsex and sexualised drug use is more 51 
common among both MSM and WSW than heterosexual men and women.52 
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Introduction 53 
Higher levels of drug use have been reported in lesbian, gay, bisexual and transgender (LGBT) as 54 
compared to heterosexual communities (Green & Feinstein, 2012; Home Office, 2014). There are 55 
likely to be various underlying reasons and motivations for drug use in the LGBT community, 56 
including sexual minority stress (including stigma, discrimination and internalised homophobia), 57 
social norms and perceived peer pressures (Green & Feinstein, 2012; Ramchand, Fisher, Griffin, 58 
Becker, & Iguchi, 2013). Sexualised drug use has been reported to be common among men who have 59 
sex with men (MSM) in the UK and elsewhere (Melendez-Torres, Hickson, Reid, Weatherburn, & 60 
Bonell, 2017; Mohammed, et al., 2016). Sexualised drug use can take many forms and is not a new 61 
phenomenon, hoǁeǀer, seǆ uŶder the iŶflueŶĐe of preǀiouslǇ popular ͚Đluď drugs͛ suĐh as eĐstasǇ 62 
and cocaine, was often incidental rather than planned and intentional (Bourne, et al., 2015). The 63 
emergence over the last decade or so of ͚Đheŵseǆ͛ or ͚PartǇ aŶd PlaǇ ;PŶPͿ͛ where particular drugs 64 
are used before or during planned sexual activity to sustain, enhance, disinhibit or facilitate sex 65 
among MSM, has caused particular concern (Bourne, et al., 2015; Public Health England, 2015). The 66 
drugs used in chemsex/PnP can vary among and within countries (Schmidt, et al., 2016). In the UK,  67 
they usually include one or more of mephedrone, GHB/GBL, methamphetamine and less commonly 68 
ketamine (Bourne, Reid, Hickson, Torres-Rueda, & Weatherburn, 2014; Schmidt, et al., 2016); with 69 
the injecting use in this context often referred to as ͚slaŵŵiŶg͛ (Bourne, et al., 2015). Among certain 70 
populations chemsex/PnP is associated with increased sexual risk behaviour, and so an elevated risk 71 
of blood borne and sexually transmitted infections. In addition, sharing equipment when injecting 72 
drugs may put individuals at greater risk of both HIV and Hepatitis C infection (Public Health England, 73 
Health Protection Scotland, Public Health Wales, & Public Health Agency Northern Ireland, 2017). 74 
Injecting drug use in England, Wales and Northern Ireland is monitored by the unlinked anonymous 75 
monitoring (UAM) survey of people who inject drugs, which samples from a range of generic drug 76 
services (including needle and syringe programmes (NSPs) and drug and alcohol treatment services). 77 
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Since 2000, the proportion of all male PWID recruited in the UAM survey who reported sex with men 78 
has increased from 4% in 2000/01 to 8% in 2014/15 (Glass, Hope, Tanner, & Desai, 2017). MSM were 79 
more often recent initiates to injecting as compared to heterosexual men (13% vs. 8%) (Glass, et al., 80 
2017). These findings indicated that a shift in the injecting population attending drug services is 81 
occurring, warranting further investigation of drug use amongst MSM populations.  82 
Although drug use amongst MSM is widely reported, limited information is available on the extent of 83 
sexualised drug use amongst MSM (Edmundson, et al.). For women who have sex with women 84 
(WSW), there is currently very little information available on the extent and nature of any drug use, 85 
including sexualised drug use (Beddoes, Sheikh, Khanna, & Francis, 2010; Moncrief, 2014). In the 86 
context of the recent emergence of chemsex/PnP, and in particular ͚slaŵŵiŶg͛, we explored the 87 
types of drugs used by sexual behaviour among men and women who inject drugs in England, Wales 88 
and Northern Ireland so as to better understand the current patterns of injecting and non-injecting 89 
drug use among MSM and WSW who inject drugs.  90 
 91 
Methods 92 
Study population 93 
A repeated, national, voluntary unlinked-anonymous survey of people who inject drugs in the UK 94 
(excluding Scotland) has been conducted since 1990. The full methodology of the survey has been 95 
previously described (Hope, et al., 2014). Briefly, between 2500-3500 PWID attending a range of 96 
services were recruited each year into the survey by around 60 collaborating agencies; these include 97 
addiction treatment services, community drug and alcohol teams, and NSPs. Eligible participants 98 
included those who had ever injected psychoactive drugs and who had not already participated in 99 
the current calendar year. Participants provided a dried-blood spot sample, which was tested for 100 
antibodies against HIV, hepatitis B and hepatitis C, and self-completed a questionnaire which 101 
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gathered data on: injected drugs in the past year and past month; non-injected drug use in the past 102 
month; sharing of needles, syringes and other injecting equipment in the past month; and sexual 103 
behaviour including the number of male and female partners in the past year, condom use, and 104 
involvement in transactional sex in the past year. First participations during 2013-2016 were 105 
included (i.e. those taking part in 2014 to 2016 who reported taking part previously since 2013 were 106 
excluded as repeats) with reports of having sex and injecting drugs in the past year.  107 
Definitions 108 
MSM was defined as any male participant who reported sex with at least one male in the past year, 109 
regardless of the number of female sexual partners reported. Similarly, WSW was defined as any 110 
female participant who reported sex with at least one female in the past year, regardless of the 111 
number of male sexual partners reported. We defined injected and non-injected mephedrone and 112 
ketamine as drugs associated with chemsex/PnP (the survey questionnaire did not ask about 113 
GHB/GBL and methamphetamine use during this period). Direct sharing was defined as the sharing 114 
of needles and syringes. Indirect sharing was defined as the sharing of other injecting paraphernalia, 115 
such as spoons and filters. Total number of sexual partners was calculated by adding the number of 116 
male and female sexual partners, and was categorised as those reporting <10 or 10+ sexual partners. 117 
Information on those individuals who reported information on <10 male or female partners only, but 118 
left the question blank for the other gender were included in the group with <10 sexual partners. 119 
Sexual risk was defined as reporting 10+ sexual partners, and/or not always using a condom (for men 120 
and heterosexual women only), and/or being involved in transactional sex. Transactional sex was 121 
defined as receiving money, goods or drugs in exchange for sex. 122 
Analysis 123 
Injecting and non-injecting drug use was compared between MSM and heterosexual men, and 124 
between WSW and heterosexual women. For injected drugs, use in the past year was used for 125 
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analysis to increase the power of the analysis and to capture information on intermittent injectors as 126 
well as regular injectors. A sensitivity analysis was performed using injected drug use in the past 127 
month. For non-injected drug use only data on use in the past month was available. For MSM and 128 
WSW, associations of injected and non-injected drug use were investigated for HIV-status and for 129 
reporting opposite sex sexual partners, having 10+ sexual partners, and having transactional sex in 130 
the past year. 131 
Direct sharing of needles and syringes, and both direct and indirect sharing including other injecting 132 
paraphernalia, was compared between MSM/WSW and heterosexual men and women, between 133 
HIV-positive and HIV-negative MSM, between MSM/WSW reporting 10+ vs. <10 sexual partners, and 134 
between MSM/WSW reporting transactional sex or not.  135 
Comparisons of categorical data were conducted usiŶg PearsoŶ͛s Chi-squared test and comparisons 136 
of numeric data were conducted usiŶg the StudeŶt͛s t-test or Mann-Whitney U-test as appropriate. 137 
Odds ratios (OR) and 95% confidence intervals (CI) for the types of injected and non-injected drug 138 
used were adjusted by logistic regression for age and geography (region/country of attended drug 139 
service) a priori and for homelessness and imprisonment if found to differ by sexual behaviour on 140 
univariate analysis.  141 
Results 142 
Study population 143 
Between 2013 and 2016, there were 7,440 first participations who reported injecting drugs in the 144 
past year. Sexual activity in the past year was reported for 4,972 individuals (67%), with those 145 
sexually active individuals being younger (mean age 36 for sexually active vs. 41 years for sexually 146 
inactive, p<0.001) and more likely to be female (29% female for sexually active vs. 17% female for 147 
sexually inactive, p<0.001). There were 299 MSM, 3,215 heterosexual male, 122 WSW and 1,336 148 
heterosexual female participants (Table 1). Sex with women was reported by 135 (45%) of the MSM, 149 
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and sex with men was reported by 85 (70%) of the WSW. Male participants were older than female 150 
participants (p<0.001), and heterosexual females were older than WSW (p=0.004), but there was no 151 
difference in age between heterosexual males and MSM (p=0.81). A larger proportion of MSM than 152 
heterosexual men lived in London (p=0.002). A larger proportion of heterosexual men as compared 153 
to MSM had ever been homeless (p=0.01) or imprisoned (p<0.001), whereas for females 154 
imprisonment was more common amongst WSW than heterosexuals (p=0.02).  155 
Table 1: Characteristics of study participants 
 MSM Heterosexual 
male 
WSW Heterosexual 
female 
Total 299 3,215 122 1,336 
Demographics     
Age in years (mean, sd)* 36 (8.5) 36 (7.9) 32 (7.7) 34 (7.4) 
Geography (n,%) 
Living in London 
 
39 (13%) 
 
253 (7.9%) 
 
11 (9.0%) 
 
138 (10%) 
Ever homeless** (n,%) 218 (74%) 2,549 (80%) 98 (81%) 1,107 (77%) 
Ever in prison*** (n,%) 200 (68%) 2,513 (79%) 74 (62%) 675 (51%) 
HIV status     
HIV status (n, %) 16 (5.4%) 20 (0.62%) 1 (0.82%) 10 (0.75%) 
Sexual behaviour in the past year     
Sexual activity with individuals of 
the same sex and of opposite sex 
135 (45%) NA 85 (70%) NA 
Transactional sex$ 41 (14%) 53 (1.7%) 48 (41%) 255 (19%) 
10+ sexual partners#  80 (27%) 126 (4.0%) 26 (21%) 106 (8.1%) 
9 
 
Injecting risk behaviour in the past 
month
^
 
    
Injected in the past month  242 (82%) 2,473 (77%) 100 (82%) 1,012 (76%) 
Sharing of needles and syringes^ 55 (24%) 382 (16%) 32 (33%) 225 (23%) 
Sharing of needles, syringes and 
other injecting equipment^ 
114 (49%) 924 (38%) 52 (54%) 471 (48%) 
* Age missing for 37 participants, ** Homelessness missing for 41 participants, *** Imprisonment missing for 38 156 
participants, 
$
 Receiving money, goods or drugs in exchange for sex; missing for 82 participants, 
#
Number of sexual 157 
partners missing for 128 participants, 
^
Among those who reported injecting drug use in the past month (missing for 28). 158 
Sharing of needles and syringes missing for 115 participants; sharing of needles, syringes and other injecting equipment 159 
missing for 84 participants.   160 
 161 
In total, 4,859 participants (98%) provided information on the type of injected drugs used and 4,495 162 
participants (90%) provided information on the type of non-injected drugs used. Heroin was the 163 
most commonly used injected drug, reported by 85% of MSM, 93% of heterosexual men, 93% of 164 
WSW and 94% of heterosexual women (Table 2, Table 3). Crack was the most commonly used non-165 
injected drug, reported by 53% MSM, 55% heterosexual men, 66% WSW, and 55% heterosexual 166 
women.  167 
Drugs use in MSM vs. heterosexual men 168 
MSM were more likely than heterosexual men to use drugs associated with chemsex: injected or 169 
non-injected mephedrone and injected or non-injected ketamine (Table 2). MSM were also more 170 
likely to inject methadone, or inhale solvents, take ecstasy, cocaine or speed. Also unspecified 171 
͚other͛ iŶjeĐted drug use was higher among MSM. Results were similar when considering injecting 172 
drug use in the last month (Supplementary Table 1). 173 
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MSM were less likely than heterosexual men to inject heroin (Table 2), particularly those reporting 174 
only male partners (130/161, 81% vs. 120/132, 91%). Among MSM, those reporting male and female 175 
partners when compared to those reporting only male partners, more frequently reported the use of 176 
non-injected heroin (64/121, 53% vs 50/143, 35%), crack (78/121, 65% vs. 63/143, 44%) or cannabis 177 
(63/121, 52% vs. 55/143, 38%), and less frequently injecting speed (30/132, 23% vs. 55/161, 34%). 178 
MSM reporting use of drugs that have been associated with chemsex were attending services across 179 
England and Wales (results not shown). 180 
The number of different types of injected drugs used in the past year and non-injected drugs used in 181 
the past month did not differ between MSM and heterosexual men: both groups reported a median 182 
number of two injected (mean 2.2) and two non-injected drugs (mean 2.1) (p= 0.35, p=0.15). Among 183 
MSM, a higher number of non-injected drugs was reported among those also reporting sex with 184 
women (median 3 vs. median 2, p=0.005).  185 
Direct sharing of needles and syringes in the past month was reported by more MSM than 186 
heterosexual men (Table 1, p<0.001). When the sharing of spoons and filters as well as needles and 187 
syringes was considered almost half MSM reported sharing and compared to almost two-fifths of 188 
the heterosexual men (Table 1, p<0.001). 189 
 190 
Table 2: Injected drug use in the last year and non-injected drug use in the last month for MSM 
and heterosexual men 
 MSM  
n (%)  
Heterosexual 
men n (%) 
OR*, 95%CI AOR**, 95%CI 
Number of participants     
Total 299 3,215 - - 
Total with information on 292 (98%) 3,133 (97%) - - 
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injected drug use 
Total with information on 
non-injected drug use 
264 (88%) 2,908 (90%) - - 
Drugs associated with chemsex 
Mephedrone - injected 45 (15%) 259 (8.3%) 2.02 (1.44-2.85) 2.22 (1.54-3.22) 
Mephedrone - non-injected 40 (15%) 246 (8.5%) 1.93 (1.35-2.77) 2.15 (1.48-3.11) 
Ketamine - injected 31 (11%) 166 (5.3%) 2.12 (1.42-3.18) 1.98 (1.29-3.05) 
Ketamine - non-injected 25 (9.5%) 106 (3.7%) 2.77 (1.75-4.36) 2.57 (1.59-4.15) 
Other drugs - injected     
Heroin 250 (85%) 2,919 (93%) 0.46 (0.32-0.65) 0.46 (0.32-0.67) 
Methadone 24 (8.2%) 120 (3.8%) 2.25 (1.43-3.55) 2.21 (1.37-3.57) 
Crack 148 (51%) 1,604 (51%) 0.98 (0.77-1.25) 0.94 (0.72-1.22) 
Cocaine 57 (19%) 528 (17%) 1.19 (0.88-1.62) 1.23 (0.90-1.70) 
Amphetamine (speed) 85 (29%) 888 (28%) 1.04 (0.80-1.35) 1.18 (0.88-1.57) 
Other 52 (18%) 342 (11%) 1.77 (1.29-2.44) 1.85 (1.33-2.57) 
Other drugs – non-injected     
Heroin 114 (43%) 1,391 (48%) 0.83 (0.64-1.07) 0.82 (0.63-1.06) 
Crack 141 (53%) 1,593 (55%) 0.95 (0.74-1.22) 0.93 (0.71-1.22) 
Cocaine 71 (27%) 526 (18%) 1.67 (1.25-2.22) 1.64 (1.21-2.21) 
Amphetamine (speed) 56 (21%) 469 (16%) 1.40 (1.03-1.91) 1.59 (1.14-2.21) 
Cannabis 118 (45%) 1,389 (48%) 0.88 (0.69-1.14) 0.88 (0.68-1.15) 
Solvents or glue 14 (5.3%) 69 (2.4%) 2.30 (1.28-4.15) 2.56 (1.40-4.69) 
Ecstasy/MDMA 37 (14%) 190 (6.5%) 2.33 (1.60-3.40) 2.35 (1.60-3.46) 
Benzodiazepines 82 (31%) 1,065 (37%) 0.78 (0.59-1.02) 0.85 (0.64-1.13) 
None of the above 31 (12%) 388 (13%) 0.86 (0.59-1.28) 0.82 (0.55-1.24) 
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* Odds ratio for MSM compared to heterosexual men. ** Odds ratio adjusted for age, region/country of 191 
attended service, ever homeless and ever imprisonment.  192 
Drugs use in WSW vs. heterosexual women 193 
WSW were more likely than heterosexual women to use non-injected mephedrone and use injected 194 
or non-injected ketamine (Table 3). Weak evidence was found for an association with injected 195 
mephedrone. WSW were also more likely to inject methadone, inject cocaine, or inject unspecified 196 
͚other͛ drugs. Similar results were obtained in the sensitivity analysis on injected drug use in the last 197 
month, where significant results were also obtained for injected mephedrone, ketamine and crack 198 
(Supplementary Table 2). WSW were more likely to use non-injected cocaine or crack or take 199 
benzodiazepines or ecstasy, inhale solvents, or smoke cannabis. Weak evidence was found for an 200 
association with non-injected speed (Table 3). WSW reporting use of drugs that have been 201 
associated with chemsex were attending services across England and Wales (results not shown). 202 
WSW who also reported male sexual partners were more likely to report injecting crack (43/85, 51% 203 
vs. 8/37, 22%), injecting cocaine (23/85, 28% vs. 4/37, 11%), taking ecstasy (15/83, 18% vs. 0/35, 204 
0%), smoking cannabis (53/83, 64% vs. 15/35, 43%) or snorting cocaine (28/83, 34% vs. 3/35, 8.6%). 205 
Weak evidence was obtained for injection of ketamine (12/85, 14% vs. 1/37, 2.7%, p=0.06), non-206 
injected ketamine use (8/83, 9.6% vs. 0/35, 0%, p=0.06) and injection of speed (28/85, 33% vs. 6/37, 207 
16%, p=0.06).  208 
WSW reported a higher number of different types of injected drugs (median 2, mean 2.2) than 209 
heterosexual women (median 2, mean 1.8) (p=0.003). WSW also reported a higher number of non-210 
injected drugs (median 3, mean 3.3) drugs than heterosexual women (median 2, mean 2.2) 211 
(p<0.001), and were less likely to indicate that they had used none of the listed non-injected drugs 212 
(Table 3). Among WSW, a higher number of injected and non-injected drugs was reported for those 213 
also reporting sex with men (median 1 vs. median 2, p=0.005; median 4 vs. median 2, p<0.001). 214 
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Direct sharing of needles and syringes in the last month was reported by more WSW (32/97, 33%) 215 
than heterosexual women (225/978, 23%) (p=0.03), although this difference was no longer 216 
significant when including the sharing of spoons and filters (WSW: 52/97, 54%, heterosexual women: 217 
471/988, 48%, p=0.26). Sharing of needles and syringes was more frequently reported for WSW also 218 
reporting sex with men as compared to those reporting sexual contact with females only (28/68, 219 
41% vs. 4/29, 14%, p=0.009). 220 
Table 3: Injected drug use in the last year and non-injected drug use in the last month for WSW 
and heterosexual women 
Drug used WSW 
n (%)  
Heterosexual 
women n (%) 
OR*, 95%CI AOR**, 95%CI 
Number of participants 
Total 122 1,336 - - 
Total with information on 
injected drug use 
122 
(100%) 
1,312 (98%) - - 
Total with information on 
non-injected drug use 
118 (97%) 1,205 (90%) - - 
Drugs associated with chemsex 
Mephedrone - injected 17 (14%) 92 (7.0%) 2.15 (1.23-3.74) 1.81 (0.98-3.34) 
Mephedrone - non-injected 17 (14%) 75 (6.2%) 2.54 (1.44-4.46) 2.19 (1.20-3.99) 
Ketamine - injected 13 (11%) 35 (2.7%) 4.35 (2.24-8.47) 5.58 (2.74-11.4) 
Ketamine - non-injected 8 (6.8%) 25 (2.1%) 3.43 (1.51-7.79) 3.05 (1.30-7.19) 
Other drugs - injected     
Heroin 114 (93%) 1,240 (94%) 0.87 (0.41-1.86) 0.74 (0.34-1.63) 
Methadone 14 (11%) 48 (3.7%) 3.42 (1.83-6.41) 3.86 (2.00-7.44) 
Crack 51 (42%) 530 (40%) 1.07 (0.73-1.55) 1.18 (0.78-1.78) 
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Cocaine 28 (23%) 137 (10%) 2.56 (1.62-4.05) 3.07 (1.90-4.94) 
Amphetamine (speed) 34 (28%) 331 (25%) 1.15 (0.76-1.74) 1.07 (0.68-1.67) 
Other 24 (20%) 77 (5.9%) 3.94 (2.38-6.51) 4.73 (2.74-8.14) 
Other drugs – non-injected     
Heroin 66 (56%) 606 (50%) 1.25 (0.86-1.84) 1.14 (0.77-1.70) 
Crack 78 (66%) 661 (55%) 1.60 (1.08-2.39) 1.61 (1.05-2.45) 
Cocaine 31 (26%) 168 (14%) 2.20 (1.41-3.42) 2.22 (1.41-3.50) 
Amphetamine (speed) 28 (24%) 177 (15%)  1.81 (1.15-2.84) 1.56 (0.97-2.54) 
Cannabis 68 (58%) 488 (41%) 2.00 (1.36-2.93) 1.91 (1.29-2.84) 
Solvents or glue 10 (8.5%) 23 (1.9%) 4.76 (2.21-
10.26) 
3.91 (1.74-8.78) 
Ecstasy/MDMA 15 (13%) 54 (4.5%) 3.10 (1.69-5.69) 3.20 (1.69-6.04) 
Benzodiazepines 68 (58%) 426 (35%) 2.49 (1.69-3.65) 2.50 (1.67-3.75) 
None of the above 5 (4%) 168 (14%) 0.27 (0.11-0.68) 0.31 (0.13-0.79) 
* Odds ratio for WSW compared to heterosexual women. ** Adjusted for age, region/country of 221 
attended service, and ever imprisonment.  222 
Drug use associated with HIV in MSM 223 
Although numbers are small, there is evidence that HIV-positive MSM were more likely than HIV-224 
negative MSM to have used drugs that have been associated with chemsex: injected and non-225 
injected mephedrone and injected ketamine (Table 4). Also iŶjeĐtioŶ of uŶspeĐified ͚other͛ drugs 226 
was higher amongst HIV-positive MSM (Table 4). Injected and non-injected heroin use was lower 227 
amongst HIV-positive MSM (Table 4). 228 
Sharing of needles and syringes, and the sharing of spoons, filters, needles and/or syringes was 229 
reported by a lower proportion of HIV-positive MSM than HIV-negative MSM, although statistical 230 
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significance was only reached for the association of sharing of spoons, filters, needles and/or 231 
syringes (HIV-positive MSM: 3/14, 21% vs. HIV-negative MSM: 111/218, 51%, p=0.03). 232 
Of the sixteen HIV-positive MSM, thirteen were aware of their status, one reported never being 233 
tested, and two did not respond to the question about testing.  234 
Table 4: Injected drug use in the last year and non-injected drug use in the last month 
 for HIV-positive and HIV-negative MSM*  
Drug used HIV-positive 
n (%)  
HIV-negative  
n (%) 
OR*, 95%CI AOR**, 95%CI 
Number of participants     
Total 16 299 - - 
Total with information on 
injected drug use 
16 (100%) 277 (93%) - - 
Total with information on 
non-injected drug use 
16 (100%) 248 (83%) - - 
Mephedrone - injected 11 (69%) 34 (12%) 15.66 (5.13-
47.82) 
15.6 (3.74-
65.07) 
Mephedrone – non-injected 9 (56%) 31 (13%) 9.00 (3.13-
25.90) 
13.1 (3.00-
56.93) 
Ketamine - injected 5 (31%) 26 (9.4%) 4.37 (1.41-
13.55) 
4.06 (1.04-
15.92) 
Heroin - injected 6 (38%) 244 (88%) 0.08 (0.03-0.24) 0.17 (0.05 -0.63) 
Heroin – non-injected 0 (0%) 114 (46%) - - 
Other - injected 7 (44%) 45 (16%) 4.00 (1.42-
11.32) 
 
3.40 (1.00-
11.57) 
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* Only drugs shown significant on multivariate analysis, * Odds ratio for HIV-positive MSM compared to HIV-235 
negative MSM. ** Odds ratio adjusted for age, region/country of attended service, ever homeless and ever 236 
imprisonment.  237 
 238 
Drug use associated with 10+ sexual partners and transactional sex in MSM and WSW 239 
Reporting 10+ sexual partners in the past year was more common among MSM and WSW than 240 
heterosexual men and women (Table 1, p<0.001). Transactional sex in the last year was more 241 
commonly reported among women than men (p<0.001), and more commonly reported among MSM 242 
and WSW than heterosexual men and women (Table 1, p<0.001, p<0.001). 243 
For WSW, all of those (100%) who reported 10+ sexual partners reported also having sex with men, 244 
and 23 out of 26 (88%) who reported 10+ sexual partners reported transactional sex in the last year. 245 
Among MSM, those reporting 10+ sexual partners were no more or less likely to report also having 246 
sex with women (39/80, 49% vs. 96/219, 44%, p=0.45), but were more likely to report transactional 247 
sex than those with <10 partners (16/76, 21% vs. 25/211, 12%, p=0.05). A minority of those 248 
reporting 10+ sexual partners reported always using a condom, with consistent condom use being 249 
lower amongst MSM (11%, 7/64) and heterosexual men (15%, 17/112) than among heterosexual 250 
women (45%, 32/71) (p<0.001).  251 
Among MSM, the use of non-injected mephedrone was associated with having 10+ sexual partners 252 
(AOR 2.23, 1.02-4.88), and the use of injected mephedrone was weakly associated (AOR 2.09, 0.96-253 
4.57). Use of injected and non-injected mephedrone (AOR 1.79, 1.29-2.48; AOR 1.42, 1.00-2.00), 254 
injected ketamine (AOR 1.55, 1.09-2.22) and injected cocaine (AOR 1.42, 1.06-1.90) were associated 255 
with transactional sex in the past year. Injecting heroin (AOR 0.33, 0.14-0.81), injecting crack (AOR 256 
0.24, 0.12-0.47), smoking crack (AOR 0.53, 0.28-1.01) and injecting cocaine (AOR 0.36, 0.15-0.86) 257 
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were less frequent among MSM having 10+ sexual partners than among MSM with <10 sexual 258 
partners.  259 
Among WSW, injecting crack was associated with having 10+ sexual partners (AOR 3.53, 1.17-10.62) 260 
and with transactional sex (AOR 1.55, 1.12-2.14). Smoking crack was associated with transactional 261 
sex (AOR 1.68, 1.21-2.34). Taking ecstasy was associated with having 10+ sexual partners (AOR 5.73, 262 
1.36-24.10). Smoking heroin was associated with having 10+ sexual partners (AOR 4.26, 1.34-13.55) 263 
and with transactional sex (AOR 1.45, 1.06-1.98). Because of the strong association between having 264 
10+ sexual partners and transactional sex among WSW, it was not possible to add both variables to 265 
the same multivariate model. 266 
For MSM, there was no evidence for increased sharing of needles and syringes and other injecting 267 
paraphernalia for those reporting 10+ sexual partners (10+: 29/64, 45% vs. <10: 85/168, 51%; 268 
p=0.47), but there was evidence for increased sharing of injecting equipment among those involved 269 
in transactional sex in the past year (needle and/or syringe sharing: transactional sex, 16/35, 46% vs. 270 
no transactional sex, 35/184, 19%, p=0.001; sharing of spoons, filters, needles and/or syringes: 271 
transactional sex, 28/36, 78% vs. no transactional sex, 79/186, 42%, p<0.001).  272 
For WSW, both sharing of needles and syringes and other injecting paraphernalia were higher 273 
amongst those reporting 10+ sexual partners (needles and/or syringes: 10+: 13/23, 57% vs. <10: 274 
19/74, 26%, p=0.006; sharing of spoons, filters, needles and/or syringes: 10+: 18/23, 78% vs. <10: 275 
34/74: 46%, p=0.007) and amongst those reporting transactional sex (needle and/or syringe sharing: 276 
transactional sex, 21/43, 49% vs. no transactional sex, 8/51, 16%, p=0.001; sharing of spoons, filters, 277 
needles and/or syringes: transactional sex, 28/43, 65% vs. no transactional sex, 21/51, 41% ,p=0.02). 278 
 279 
 280 
  281 
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Discussion 282 
Injecting and non-injecting drug use differed between MSM and WSW and heterosexual men and 283 
women who inject drugs in our study. Mephedrone and ketamine use, drugs associated with 284 
chemsex, were found to be higher in MSM and WSW, but there were also differences by sexual 285 
behaviour for a number of other drugs, including drugs, such as cocaine, crack, cannabis and 286 
amphetamine, that can be used for sexualised drug use. Injected and particularly non-injected drug 287 
use was reported to be higher for WSW and MSM also reporting sexual partners of the opposite sex. 288 
Mephedrone and ketamine were also associated with a positive HIV-status and with transactional 289 
sex among MSM, and mephedrone was associated with having a large number of sexual partners in 290 
MSM. We also identified higher injecting and sexual risks among MSM/WSW as compared to 291 
heterosexual men and women, with a higher proportion of MSM and WSW reporting sharing of 292 
needles and syringes, having 10+ sexual partners, and being involved in transactional sex. Consistent 293 
condom use was low amongst both MSM and heterosexual men and women with 10+ partners.  294 
 295 
Our findings need to be considered in the context of the study population of the UAM survey; that is 296 
people who have ever injected psychoactive drugs recruited through a range of services including 297 
addiction treatment services and NSPs. This population will differ from the wider, mostly non-298 
injecting, drug using population of MSM/WSW; for example, our sample had much larger proportion 299 
of heroin or crack use compared to other studies, and a high proportion of WSW involved in 300 
transactional sex. Despite these caveats, our survey suggests that drug use patterns are different 301 
between MSM/WSW and heterosexual individuals who inject drugs, and this may in part be 302 
explained by sexualised drug use. 303 
 304 
19 
 
The UK Drug PoliĐǇ CoŵŵissioŶ͛s ϮϬϭϬ report identified a lack of information relating to lesbian and 305 
bisexual women (Moncrief, 2014). Our study is one of the first studies to highlight differences in 306 
drug use in WSW as compared to heterosexual women in the UK (Beddoes, et al., 2010; Moncrief, 307 
2014), albeit among a sample of people who injected drugs and attended services. We found that 308 
WSW were more likely than heterosexual women to use mephedrone and ketamine, but also 309 
various other injected and non-injected drugs. Drug use patterns in WSW were associated with 310 
having sex with men, transactional sex and reporting 10+ sexual partners, but it was not possible to 311 
disentangle the individual contribution of those factors due to the strong associations between 312 
these factors and the small sample size. Sex with men and women and/or identifying as bisexual 313 
have been reported in the literature to be associated with higher drug use (Barker, et al., 2012; 314 
Buffin, Roy, Williams, & Winter, 2012; Green & Feinstein, 2012; Kerr, Ding, Burke, & Ott-Walter, 315 
2015; King & McKeown, 2003). 316 
 317 
Until recently, little information was available on use of drugs associated with sexualised drug use 318 
amongst MSM (Beddoes, et al., 2010; Bourne, et al., 2014). In recent years, more evidence has 319 
become available on the prevalence, and the drivers of sexualised drug use and chemsex (Ahmed, et 320 
al., 2016; Bourne, et al., 2015; Daskalopoulou, et al., 2014; Schmidt, et al., 2016), although limited 321 
information remains available on the extent of the injection of drugs associated with chemsex 322 
;͚slaŵŵiŶg͛Ϳ. Our surǀeǇ addressed ďoth iŶjeĐted aŶd ŶoŶ-injected drug use in people who inject 323 
drugs attending services in England, Wales and Northern Ireland.  Among MSM overall, we found 324 
15% had injected mephedrone in the past year and 15% used mephedrone through other non-325 
injected routes during the past month. However, among those MSM who were HIV-positive 69% had 326 
injected mephedrone in the past year and 56% mephedrone used it through other routes. Our 327 
estimates fit within the those reported in the wider literature (Edmundson, et al.), when considering 328 
that our study population only included those who injected drugs in the past year attending generic 329 
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services. Comparisons of the literature on sexualised drug use and chemsex among MSM are difficult 330 
due to the range of definitions and recall periods used, lack of event-level data, and differing 331 
recruitment strategies and study populations (Edmundson, et al.).  332 
 333 
We found broadly similar patterns of drug use in MSM and WSW, with the exception of smoking 334 
cannabis and use of non-prescribed benzodiazepines which were more likely to be reported by 335 
WSW. There is little published data available on the comparison between drug use in MSM and 336 
WSW. A community-based survey of 4,165 LGB people in the UK found that use in the last month of 337 
all substances studied, apart from cannabis, was higher for MSM than for WSW (Buffin, et al., 2012). 338 
No distinction in the publication was made between injected and non-injected drug use.  339 
 340 
Apart from sexualised drug use, there are other factors that should be considered to explain the 341 
difference in drug use patterns between MSM/WSW and heterosexuals. Poorer mental health, 342 
including higher rates of anxiety, depression, self-harm and suicide have been observed among LGBT 343 
populations when compared to heterosexual people (Jorm, Korten, Rodgers, Jacomb, & Christensen, 344 
2002; King, et al., 2003), with higher rates observed particularly in those identifying as bisexual 345 
(Barker, et al., 2012; Jorm, et al., 2002). Among MSM/WSW poorer mental health is often associated 346 
with experiencing stigma, violence and verbal assault (Barker, et al., 2012; King, et al., 2003). Mental 347 
health is strongly linked to drug use (NIDA, 2014), and could explain differences in the drug patterns 348 
observed in this study. Accessible and appropriate mental health services for those MSM/WSW 349 
involved in drug use, including sexualised drug use and chemsex, should be provided. Social norms 350 
aŶd perĐeptioŶs of peers͛ ďehaǀiour have also been linked to drug use (NIDA, 2014), and have been 351 
described among gay and bisexual men taking ͚partǇ drugs͛ (Ramchand, et al., 2013), including 352 
21 
 
chemsex drugs (Ahmed, et al., 2016). There is a need for health promotion interventions to 353 
challenge social norms relating to drug use generally, and chemsex specifically (Ahmed, et al., 2016). 354 
 355 
Most evidence available on sexualised drug use in MSM/WSW populations is collected through 356 
sexual health clinics. Edmundson et al. found that nineteen of twenty-eight studies included in a 357 
literature review on sexualised drug use among MSM in the UK were conducted in HIV and/or sexual 358 
health clinics, and two in a specialised LGBT drug and alcohol clinic in London. In the specialised 359 
London clinic a much higher prevalence of chemsex drugs use was observed than in our survey: 64% 360 
attended the clinic for mephedrone (Moncrief, 2014), and 85% for any chemsex drug (Stuart, 2013), 361 
which is unsurprising given the LGBT focus of the clinic and its particular interest in chemsex. Our 362 
study provides new evidence for injected and non-injected drug use among MSM/WSW attending 363 
generic services with the use of drugs associated with chemsex reported across England and Wales. 364 
There were notable differences by sexual behaviour for a number of other drugs, including drugs 365 
that could be used in other patterns of sexualised drug use such as cocaine, crack, cannabis and 366 
amphetamine. Although we cannot conclude from our data whether individuals sought treatment or 367 
advice for sexualised drug use when attending the drug services, it does suggest that use of 368 
sexualised drugs does occur among individuals attending drug service, and that tailored services 369 
need to be available when an individual does seek help. 370 
 371 
Sharing of needles and syringes was reported more frequently amongst MSM and WSW as 372 
compared to heterosexual men and women in our study. Sharing of needles and syringes was 373 
particularly high among WSW with 10+ sexual partners and among MSM and WSW reporting 374 
transactional sex, placing them at increased risk of blood borne virus infections, including HIV and 375 
hepatitis C. Sharing of needles and syringes was found to be lower amongst HIV-positive MSM than 376 
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amongst HIV-negative MSM. Almost all HIV-positive MSM included in the survey were aware of their 377 
status; fear of transmitting the virus to others may have been the reason for reduced sharing of 378 
injecting equipment.  379 
 380 
Several limitations could be identified for our study. We cannot conclude whether differences in 381 
drug use between MSM/WSW and heterosexual men and women relate specifically to sexualised 382 
drug use, because the questionnaire did not include a question on whether drugs were used during 383 
sex. The types of drugs used and the associations with many sexual partners among MSM suggest 384 
that sexualised drug use, iŶĐludiŶg ͚slaŵŵiŶg͛ does occur. Another limitation of the questionnaire 385 
used is that it did not collect data on GHB/GBL and methamphetamine use during this period, both 386 
of which are common chemsex drugs. For iŶjeĐtiŶg drug use, aŶ uŶspeĐified ͚other͛ ĐategorǇ ǁas 387 
included in the questionnaire: this was reported more frequently for MSM and WSW as compared to 388 
heterosexuals, and reported more frequently among HIV-positive MSM as compared to HIV-negative 389 
MSM, possibly capturing some injected methamphetamine or GHB/GBL use. Questions on 390 
methamphetamine and GHB/GBL have been added to the questionnaire used in the UAM survey 391 
from 2017 onwards. The UAM survey included questions on sexual behaviour, but not on sexual 392 
identity, and it is possible that those who were included in the analysis as MSM/WSW would not 393 
identify as such (Green & Feinstein, 2012). Other limitations of the survey are its cross-sectional 394 
study design, which prohibits inferences on the causal directions of associations, and its reliance on 395 
self-reported behaviour. The accuracy of self-reports may be subject to recall bias; however, self-396 
reported risk behaviours among PWID have previously been shown to be reliable (Latkin, Vlahov, & 397 
Anthony, 1993). Further, the survey used a self-completed and anonymous questionnaire to reduce 398 
disclosure bias, however, concerns about the disclosure of sensitive issues, such as sexual behaviour, 399 
might still persist and socially desirable answers could have been given for these.  400 
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Our analysis adds to the growing body of evidence that seǆualised drug use, iŶĐludiŶg ͚slaŵŵiŶg͛ is 401 
occurring among MSM accessing generic drug services, and provides new evidence indicating 402 
sexualised drug use, including ͚slaŵŵiŶg͛, might be occurring among WSW accessing generic 403 
services. Our analysis further highlights that injected and non-injected drug use overall are different 404 
between MSM/WSW and heterosexual men and women. Though further work is needed, 405 
understanding these differences in drug use by sexual behaviour are important to our understanding 406 
of current patterns of sexualised drug, including chemsex, and for framing appropriate responses. 407 
Although MSM/WSW may be more familiar with attending sexual health services if they require help 408 
with sexualised drug use, our data suggest that individuals who use chemsex drugs are also 409 
attending generic services for people who use drug across England, Wales and Northern Ireland. 410 
Services for people who use drugs have been encouraged to be more inclusive of LGBT communities 411 
in recent years (Public Health England, 2015), and this could be an explanation for the increased 412 
proportion of MSM recruited in to the survey in recent years, but there is scope for further 413 
improvement. Generic services for people who use and inject drug in the UK are mostly set up to 414 
address opiate use and may be less familiar with treatments for stimulant drug use, particularly for 415 
the drugs associated with sexualised drug use. Although heroin use is still most commonly reported 416 
amongst those attending these generic services, including in MSM/WSW, these services may need to 417 
be adapted to meet the local needs of MSM/WSW who present and may have problems related to 418 
sexualised drug use, including chemsex (Public Health England, 2015).  419 
  420 
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Table 1: Characteristics of study participants 
 MSM Heterosexual 
male 
WSW Heterosexual 
female 
Total 299 3,215 122 1,336 
Demographics     
Age in years (mean, sd)* 36 (8.5) 36 (7.9) 32 (7.7) 34 (7.4) 
Geography (n,%) 
Living in London 
 
39 (13%) 
 
253 (7.9%) 
 
11 (9.0%) 
 
138 (10%) 
Ever homeless** (n,%) 218 (74%) 2,549 (80%) 98 (81%) 1,107 (77%) 
Ever in prison*** (n,%) 200 (68%) 2,513 (79%) 74 (62%) 675 (51%) 
HIV status     
HIV status (n, %) 16 (5.4%) 20 (0.62%) 1 (0.82%) 10 (0.75%) 
Sexual behaviour in the past year     
Sexual activity with individuals of 
the same sex and of opposite sex 
135 (45%) NA 85 (70%) NA 
Transactional sex$ 41 (14%) 53 (1.7%) 48 (41%) 255 (19%) 
10+ sexual partners#  80 (27%) 126 (4.0%) 26 (21%) 106 (8.1%) 
Injecting risk behaviour in the past 
month
^
 
    
Injected in the past month  242 (82%) 2,473 (77%) 100 (82%) 1,012 (76%) 
Sharing of needles and syringes^ 55 (24%) 382 (16%) 32 (33%) 225 (23%) 
Sharing of needles, syringes and 
other injecting equipment^ 
114 (49%) 924 (38%) 52 (54%) 471 (48%) 
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* Age missing for 37 participants, ** Homelessness missing for 41 participants, *** Imprisonment missing for 38 520 
participants, 
$
 Receiving money, goods or drugs in exchange for sex; missing for 82 participants, 
#
Number of sexual 521 
partners missing for 128 participants, 
^
Among those who reported injecting drug use in the past month (missing for 28). 522 
Sharing of needles and syringes missing for 115 participants; sharing of needles, syringes and other injecting equipment 523 
missing for 84 participants.   524 
  525 
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 526 
Table 2: Injected drug use in the last year and non-injected drug use in the last month for MSM 
and heterosexual men 
 MSM  
n (%)  
Heterosexual 
men n (%) 
OR*, 95%CI AOR**, 95%CI 
Number of participants     
Total 299 3,215 - - 
Total with information on 
injected drug use 
292 (98%) 3,133 (97%) - - 
Total with information on 
non-injected drug use 
264 (88%) 2,908 (90%) - - 
Drugs associated with chemsex 
Mephedrone - injected 45 (15%) 259 (8.3%) 2.02 (1.44-2.85) 2.22 (1.54-3.22) 
Mephedrone - non-injected 40 (15%) 246 (8.5%) 1.93 (1.35-2.77) 2.15 (1.48-3.11) 
Ketamine - injected 31 (11%) 166 (5.3%) 2.12 (1.42-3.18) 1.98 (1.29-3.05) 
Ketamine - non-injected 25 (9.5%) 106 (3.7%) 2.77 (1.75-4.36) 2.57 (1.59-4.15) 
Other drugs - injected     
Heroin 250 (85%) 2,919 (93%) 0.46 (0.32-0.65) 0.46 (0.32-0.67) 
Methadone 24 (8.2%) 120 (3.8%) 2.25 (1.43-3.55) 2.21 (1.37-3.57) 
Crack 148 (51%) 1,604 (51%) 0.98 (0.77-1.25) 0.94 (0.72-1.22) 
Cocaine 57 (19%) 528 (17%) 1.19 (0.88-1.62) 1.23 (0.90-1.70) 
Amphetamine (speed) 85 (29%) 888 (28%) 1.04 (0.80-1.35) 1.18 (0.88-1.57) 
Other 52 (18%) 342 (11%) 1.77 (1.29-2.44) 1.85 (1.33-2.57) 
Other drugs – non-injected     
Heroin 114 (43%) 1,391 (48%) 0.83 (0.64-1.07) 0.82 (0.63-1.06) 
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Crack 141 (53%) 1,593 (55%) 0.95 (0.74-1.22) 0.93 (0.71-1.22) 
Cocaine 71 (27%) 526 (18%) 1.67 (1.25-2.22) 1.64 (1.21-2.21) 
Amphetamine (speed) 56 (21%) 469 (16%) 1.40 (1.03-1.91) 1.59 (1.14-2.21) 
Cannabis 118 (45%) 1,389 (48%) 0.88 (0.69-1.14) 0.88 (0.68-1.15) 
Solvents or glue 14 (5.3%) 69 (2.4%) 2.30 (1.28-4.15) 2.56 (1.40-4.69) 
Ecstasy/MDMA 37 (14%) 190 (6.5%) 2.33 (1.60-3.40) 2.35 (1.60-3.46) 
Benzodiazepines 82 (31%) 1,065 (37%) 0.78 (0.59-1.02) 0.85 (0.64-1.13) 
None of the above 31 (12%) 388 (13%) 0.86 (0.59-1.28) 0.82 (0.55-1.24) 
* Odds ratio for MSM compared to heterosexual men. ** Odds ratio adjusted for age, region/country of 527 
attended service, ever homeless and ever imprisonment.  528 
  529 
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Table 3: Injected drug use in the last year and non-injected drug use in the last month for WSW 
and heterosexual women 
Drug used WSW 
n (%)  
Heterosexual 
women n (%) 
OR*, 95%CI AOR**, 95%CI 
Number of participants 
Total 122 1,336 - - 
Total with information on 
injected drug use 
122 
(100%) 
1,312 (98%) - - 
Total with information on 
non-injected drug use 
118 (97%) 1,205 (90%) - - 
Drugs associated with chemsex 
Mephedrone - injected 17 (14%) 92 (7.0%) 2.15 (1.23-3.74) 1.81 (0.98-3.34) 
Mephedrone - non-injected 17 (14%) 75 (6.2%) 2.54 (1.44-4.46) 2.19 (1.20-3.99) 
Ketamine - injected 13 (11%) 35 (2.7%) 4.35 (2.24-8.47) 5.58 (2.74-11.4) 
Ketamine - non-injected 8 (6.8%) 25 (2.1%) 3.43 (1.51-7.79) 3.05 (1.30-7.19) 
Other drugs - injected     
Heroin 114 (93%) 1,240 (94%) 0.87 (0.41-1.86) 0.74 (0.34-1.63) 
Methadone 14 (11%) 48 (3.7%) 3.42 (1.83-6.41) 3.86 (2.00-7.44) 
Crack 51 (42%) 530 (40%) 1.07 (0.73-1.55) 1.18 (0.78-1.78) 
Cocaine 28 (23%) 137 (10%) 2.56 (1.62-4.05) 3.07 (1.90-4.94) 
Amphetamine (speed) 34 (28%) 331 (25%) 1.15 (0.76-1.74) 1.07 (0.68-1.67) 
Other 24 (20%) 77 (5.9%) 3.94 (2.38-6.51) 4.73 (2.74-8.14) 
Other drugs – non-injected     
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Heroin 66 (56%) 606 (50%) 1.25 (0.86-1.84) 1.14 (0.77-1.70) 
Crack 78 (66%) 661 (55%) 1.60 (1.08-2.39) 1.61 (1.05-2.45) 
Cocaine 31 (26%) 168 (14%) 2.20 (1.41-3.42) 2.22 (1.41-3.50) 
Amphetamine (speed) 28 (24%) 177 (15%)  1.81 (1.15-2.84) 1.56 (0.97-2.54) 
Cannabis 68 (58%) 488 (41%) 2.00 (1.36-2.93) 1.91 (1.29-2.84) 
Solvents or glue 10 (8.5%) 23 (1.9%) 4.76 (2.21-
10.26) 
3.91 (1.74-8.78) 
Ecstasy/MDMA 15 (13%) 54 (4.5%) 3.10 (1.69-5.69) 3.20 (1.69-6.04) 
Benzodiazepines 68 (58%) 426 (35%) 2.49 (1.69-3.65) 2.50 (1.67-3.75) 
None of the above 5 (4%) 168 (14%) 0.27 (0.11-0.68) 0.31 (0.13-0.79) 
* Odds ratio for WSW compared to heterosexual women. ** Adjusted for age, region/country of 531 
attended service, and ever imprisonment.  532 
  533 
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Table 4: Injected drug use in the last year and non-injected drug use in the last month 
 for HIV-positive and HIV-negative MSM*  
Drug used HIV-positive 
n (%)  
HIV-negative  
n (%) 
OR*, 95%CI AOR**, 95%CI 
Number of participants     
Total 16 299 - - 
Total with information on 
injected drug use 
16 (100%) 277 (93%) - - 
Total with information on 
non-injected drug use 
16 (100%) 248 (83%) - - 
Mephedrone - injected 11 (69%) 34 (12%) 15.66 (5.13-
47.82) 
15.6 (3.74-
65.07) 
Mephedrone – non-injected 9 (56%) 31 (13%) 9.00 (3.13-
25.90) 
13.1 (3.00-
56.93) 
Ketamine - injected 5 (31%) 26 (9.4%) 4.37 (1.41-
13.55) 
4.06 (1.04-
15.92) 
Heroin - injected 6 (38%) 244 (88%) 0.08 (0.03-0.24) 0.17 (0.05 -0.63) 
Heroin – non-injected 0 (0%) 114 (46%) - - 
Other - injected 7 (44%) 45 (16%) 4.00 (1.42-
11.32) 
 
3.40 (1.00-
11.57) 
* Only drugs shown significant on multivariate analysis, * Odds ratio for HIV-positive MSM compared to HIV-535 
negative MSM. ** Odds ratio adjusted for age, region/country of attended service, ever homeless and ever 536 
imprisonment.  537 
